Skip to Main Content

Contribute Try STAT+ Today

Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Pharmalot By Ed Silverman

Fearing spies, Sanofi wants to nix new condo towers that will overlook a Toronto vaccine plant

"From our perspective, this is an issue of national security," said Fabien Marino, a Sanofi vice president who heads the Toronto site.

Pharmalot By Ed Silverman

Pfizer faces calls to quickly sell more Covid-19 pills to poorer countries

Pharma By Ed Silverman

Pharmalittle: Did Hal Barron hit his goals before leaving Glaxo? FDA rejects drugs from Merck and Pfizer

Clinical Trials illo

Pharma By Matthew Herper

They built a smarter approach to Covid clinical trials. Now they want to do the same for other diseases

Michel Vounatsos

The Pharmalot View By Ed Silverman

If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

All Coverage

Pharma By Ed Silverman

Pharmalittle: Pfizer and BioNTech start trial of Omicron-targeted vaccine; insulin makers boost lobbying spending

Pharmalot Coming/Going STILL

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

advertisement

Pharmalot By Ed Silverman

Pharmalittle: Alzheimer’s patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questioned

Pharmalot By Ed Silverman

Pharmalittle: 27 companies will make generic Merck Covid pills; drug-resistant infections are deadlier than HIV or malaria

Pharmalot By Ed Silverman

Analysis of JAMA and NEJM articles finds most authors failed to disclose conflicts

Pharmalot By Ed Silverman

Pharmalittle: Disease ‘reversal’ startup launches with $3 billion and biotech vets; network distributed fake Gilead HIV meds

Sen. Wyden

Pharmalot By Ed Silverman

Senate Finance chair investigates Bristol Myers over an allegedly abusive overseas tax shelter

Patent folder

Pharmalot By Ed Silverman

Patent thickets are thwarting U.S. availability of lower-cost biosimilar medicines, study finds

Pharma By Adam Feuerstein

Bristol CEO Giovanni Caforio on new drug launches and acquisitions in 2022

Pharmalot By Ed Silverman

Pharmalittle: Unilever will pursue Glaxo consumer unit despite rejection; Endo settles Florida opioid case for $65 million

Moderna syringes Texas

Pharmalot By Ed Silverman

At Davos, a ‘good news, bad news’ message emerges about Covid-19

Shkreli

Pharmalot By Ed Silverman

Martin Shkreli is ordered to pay $64 million and is banned from the pharma industry for life

Pharmalot Coming/Going STILL

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Senate committee advances Califf FDA nomination; bedraggled Biogen writes a shopping list

Eye

Pharmalot By Ed Silverman

FDA warns Chinese manufacturer for lack of vision when making sterile eye drops

Pharmalot By Ed Silverman

Pharmalittle: Lilly and Roche are also losers in the Medicare Alzheimer’s decision; former CRO owner pleads guilty to falsifying data

Eli Lilly headquarters

Pharmalot By Ed Silverman, Rachel Cohrs and Nicholas Florko

The biggest losers from Medicare’s decision on Aduhelm may be Biogen’s competitors

Pharmalot By Ed Silverman

Pharmalittle: Medicare proposes to restrict coverage of Biogen Alzheimer’s drug; Pfizer to cut its U.S. sales staff

pill dollar sign list price

Pharmalot By Ed Silverman

‘Skinny label’ for generic version of a pricey cancer drug cut costs for consumers

Pharmalot By Ed Silverman

Pharmalittle: Biogen CEO admits Alzheimer’s drug price was ‘wrong’; Becerra orders HHS to reconsider Medicare premium hike

telehealth clinical trial

Pharmalot By Ed Silverman

Trial by fire: More study protocols are experiencing substantial — and costly — changes

Pharmalot By Ed Silverman

Pharmalittle: Pfizer makes a major push into mRNA technology; Medicare decision on Alzheimer’s drug may hurt state budgets

Pfizer

Biotech By Matthew Herper and Megan Molteni

Pfizer to pay Beam $300 million in gene-editing deal, amping up its mRNA ambitions

Aduhelm Medicaid decision

Pharmalot By Ed Silverman

A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs